The World Health Organization (WHO) has granted emergency approval for the Covid vaccine made by Chinese state-owned company Sinopharm.
It is the first vaccine developed by a non-Western country to get WHO backing.
The vaccine has already been given to millions of people in China and elsewhere.
The WHO had previously only approved the vaccines made by Pfizer, AstraZeneca, Johnson & Johnson and Moderna.
But individual health regulators in various countries – especially poorer ones in Africa, Latin America and Asia – have approved Chinese jabs for emergency use.
With little data released internationally early on, the effectiveness of the various Chinese vaccines has long been uncertain.
But the WHO on Friday said it had validated the “safety, efficacy and quality” of the Sinopharm jab.
The WHO said the addition of the vaccine had “the potential to rapidly accelerate Covid-19 vaccine access for countries seeking to protect health workers and populations at risk”.
It is recommending that the vaccine be administered in two doses to those aged 18 and over.
A decision is expected in the coming days on another Chinese vaccine developed by Sinovac, while Russia’s Sputnik vaccine is under assessment.
Why does WHO backing matter?
The green light from the global health body is a guideline for national regulators that a vaccine is safe and effective.
WHO director-general Tedros Adhanom Ghebreyesus said it would give countries “confidence to expedite their own regulatory approval”.
The decision to list the Chinese vaccine for emergency use is expected to give a substantial boost to the scheme, which has been struggling with supply problems.
Prior to the WHO approval, the Sinopharm vaccine was already being widely used, with an estimated 65 million doses administered, according to reports.
In addition to China, countries already using the vaccine include the UAE, Pakistan and Hungary.
The decision on Friday to approve the vaccine for emergency use was made by the WHO’s technical advisory group, which reviewed its latest clinical data and manufacturing practices.
It said the efficacy of the vaccine for symptomatic and hospitalised cases of Covid-19 was estimated to be 79%.
The WHO noted that few adults over the age of 60 were included in clinical trials, so efficacy could not be estimated for this age group. But it said there was no reason to think that the vaccine would act differently in older recipients.
The health body is yet to reach a decision on China’s Sinovac vaccine. WHO experts on Friday said they were awaiting additional information before they could make a recommendation.
Millions of doses of that vaccine have also already been shipped to a number of countries, which have permitted its emergency usage. Source